Cellectar Biosciences, Inc.
General ticker "CLRB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $409.9M (TTM average)
Cellectar Biosciences, Inc. does not follow the US Stock Market performance with the rate: -16.7%.
Estimated limits based on current volatility of 4.3%: low 3.51$, high 3.83$
Factors to consider:
- Total employees count: 11 (-45.0%) as of 2024
- Top business risk factors: Need for additional capital, Labor/talent shortage/retention, Internal control weaknesses, Regulatory and compliance, Clinical trial uncertainties
Short-term CLRB quotes
Long-term CLRB plot
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $28.81MM | $38.96MM | $51.78MM |
| Operating Income | $-28.81MM | $-38.96MM | $-51.78MM |
| Non-Operating Income | $-3.04MM | $-3.87MM | $7.26MM |
| R&D Expense | $18.27MM | $27.27MM | $26.14MM |
| Income(Loss) | $-31.85MM | $-42.83MM | $-44.52MM |
| Taxes | $-0.06MM | $-0.06MM | $0.07MM |
| Profit(Loss)* | $-34.98MM | $-42.77MM | $-44.58MM |
| Stockholders Equity | $15.51MM | $-1.36MM | $14.29MM |
| Assets | $21.59MM | $12.08MM | $25.47MM |
| Operating Cash Flow | $-25.22MM | $-32.38MM | $-47.58MM |
| Capital expenditure | $0.23MM | $0.86MM | $0.10MM |
| Investing Cash Flow | $-0.23MM | $-0.86MM | $-0.10MM |
| Financing Cash Flow | $9.61MM | $22.94MM | $61.41MM |
| Earnings Per Share** | $-112.78 | $-66.07 | $-29.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.